Stakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in Kuwait

References

• WHO Regional Office for the Eastern Mediterranean. Country Cooperation Strategy for WHO and Kuwait 2012—2016. Nasr City, Cairo 11371, Egypt: World Health Organization. (Country Cooperation Strategy (CCS)); 2014. Available from: http://apps.who.int/iris/bitstream/handle/10665/113231/CCS_Kuwait_2014_EN_15234.pdf. [cited 2019 Mar 28.
   Google Scholar
• Central Intelligence Agency. The world Factbook. Available from: https://www.cia.gov/library/publications/the-world-factbook/geos/ku.html. [cited 2019 Mar 28.
   Google Scholar
• Kuwait Central Statistical Bureau. Population statistics. Available from: https://csb.gov.kw/Pages/Statistics_en?ID=67&ParentCatID=1. [cited 2019 Mar 28.
   Google Scholar
• Al Hussaini M, Alsaffar N, Abdulraheem A. Exploring community pharmacists’ knowledge, perception and experiences towards branded and generic medicines in Kuwait: highlighting the role of pharmacist. Bull Fac Pharm Cairo Univ. 2018;56(1):109—114. Available from: http://www.sciencedirect.com/science/article/pii/S1110093118300061. [cited 2019 Mar 28.
   Google Scholar
• Alfonso-Christancho R, Andia T, Barbosa T, Watanabe JH. Definition and classification of generic drugs across the world. Appl Health Econ Health Policy. 2015; Supplement. Available from: https://doi.org/10.1007/s40258-014-0146-1. [cited 2019 Mar 28.
   Google Scholar
• Gothe H, Schall I, Saverno K, Mitrovic M, Luzak A, Brixner D, et al. The impact of generic substitution on health and economic outcomes: a systematic review. Appl Health Econ Health Policy. 2015;13(1):21—33. Available from: https://doi.org/10.1007/s40258-014-0147-0. [cited 2019 Mar 28].
   Google Scholar
• Gallelli L, Mumoli L, Palleria C, Piro B, Russo E, Vasapollo P, et al. Safety and efficacy of generic drugs with respect to brand formulation. J Pharmacol Pharmacother. 2013;4(5):110. Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2013;volume=4;issue=5;spage=110;epage=114;aulast=Gallelli. [cited 2019 Mar 28].
   Google Scholar
• Johnston A, Holt DW. Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol. 2014;78(2):218–43.
   PubMed Web of Science ®Google Scholar
• Bate R, Jin GZ, Mathur A. Does price reveal poor-quality drugs? Evidence from 17 countries. J Health Econ. 2011;30(6):1150–63.
   PubMed Web of Science ®Google Scholar
• Newton PN, Amin AA, Bird C, Passmore P, Dukes G, Tomson G, et al. The primacy of public health considerations in defining poor quality medicines. PLoS Med. 2011;8(12). Available from: https://doi.org/10.1371/journal.pmed.1001139. [cited 2019 Mar 28.
   Google Scholar
• Brixner D, Maniadakis N, Kaló Z, Hu S, Shen J, Wijaya K. Considering Multicriteria Decision Analysis (MCDA) Simple Scoring as an Evidence-Based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets. Value Health Reg Issues. 2017;13c:1—6. Available from: http://www.valuehealthregionalissues.com/article/S2212-1099(17)30001-8/fulltext. [cited 2019 Mar 28].
   Google Scholar
• Kaló Z, Holtorf A-P, Alfonso-Cristancho R, Shen J, Ágh T, Inotai A, et al. Need for multicriteria evaluation of generic drug policies. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2015;18(2):346–51.
   PubMed Web of Science ®Google Scholar
• Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19(1):1—13. Available from: https://doi.org/10.1016/j.jval.2015.12.003. [cited 2019 Mar 28].
   Google Scholar
• Mühlbacher AC, Kaczynski A. Making good decisions in healthcare with multi-criteria decision analysis: the use, current research and future development of MCDA. Appl Health Econ Health Policy. 2016;14(1):29–40.
   PubMed Web of Science ®Google Scholar
• Kolasa K, Zah V, Kowalczyk M. How can multi criteria decision analysis support value assessment of pharmaceuticals? - findings from a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2018;18(4):379–91.
   PubMed Web of Science ®Google Scholar
• Hu S, Zhang Y, He J, Du L, Xu M, Xie C, et al. A case study of pharmaceutical pricing in China: setting the Price for off-patent originators. Appl Health Econ Health Policy. 2015;13(1):13—20. Available from: https://doi.org/10.1007/s40258-014-0150-5. [cited 2019 Mar 28].
   Google Scholar
• Tuan PL, Tuan Kiet PH, Brixner DI, Ngo VH. Development of multiple criteria decision analysis framework for off-patent pharmaceuticals decision making in Vietnam | European chamber of commerce in Vietnam [internet]. Hanoi, Vietnam: European chamber of commerce Vietnam; 2017. Available from: https://www.eurochamvn.org/node/16937. [cited 2019 Mar 28.
   Google Scholar
• Brixner D, Maniadakis N, Kaló Z, Kim K, Wijaya K. An Evidence Framework for Off-Patent Pharmaceutical Review (EFOR) for Health Technology Assessment in Emerging Markets. Value Health Reg Issues. 2018;16c:9—13. Available from: https://doi.org/10.1016/j.vhri.2018.01.003. [cited 2019 Mar 28].
   Google Scholar
• Assawamakin A, Holtorf A-P, Maniadakis N. Weighing Price and performance for decisions for multisource pharmaceutical bidding in public hospitals in Thailand. In: Reddy S, editor. Evaluation of health programs. London: INTECH Open Access Publisher; 2019. p. 14. Available from: https://www.intechopen.com/online-first/weighing-price-and-performance-for-decisions-for-multisource-pharmaceutical-bidding-in-public-hospit. [cited 2019 Mar 28].
   Google Scholar
• Inotai A, Nguyen HT, Hidayat B, Nurgozhin T, Kiet PHT, Campbell JD, et al. Guidance towards the implementation of multi-criteria decision analysis framework in developing countries. Expert Rev Pharmacoecon Outcomes Res. 2018;18(6):585–92.
   PubMed Web of Science ®Google Scholar
• Communities and Local Government. Multi-criteria analysis: a manual. Wetherby, Great Britain: Department for Communities and Local Government; 2009. Available from: http://www.communities.gov.uk/documents/corporate/pdf/1132618.pdf. [cited 2019 Mar 28.
   Google Scholar
• Inotai A, Brixner D, Maniadakis N, Dwiprahasto I, Kristin E, Prabowo A, et al. Development of multi-criteria analysis (MCDA) framework for off-patent pharmaceuticals — an application on improving tender decision making in Indonesia. BMS Health Serv Res. 2018;18(1003) (online). Available from: https://doi.org/10.1186/s12913-018-3805-3. [cited 2019 Mar 28].
   Google Scholar
• Hu S, Holtorf A-P, Wijaya K, He J, Brixner D. Value based evaluation for health insurance policy schemes in China’s provinces. In: Reddy S, editor. Evaluation of health programs [internet]. London: INTECH Open Access Publisher; 2019. Available from: https://www.intechopen.com/online-first/value-based-evaluation-of-chinese-provincial-health-insurance-policy-schemes. [cited 2019 Mar 28].
   Google Scholar